Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × Maintenance × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Gastrointestinal 1

Conditions

Neoplasm, Residual 1 Neoplasm Metastasis 1

Interventions

pembrolizumab 34 Specimen Handling 26 Magnetic Resonance Spectroscopy 26 Radiosurgery 25 Biopsy 25 Gemcitabine 22 Nivolumab 21 Paclitaxel 18 Carboplatin 16 Bevacizumab 15 Trastuzumab 14 Everolimus 12 Radiotherapy 11 Irinotecan 11 trastuzumab deruxtecan 10 atezolizumab 10 Erlotinib Hydrochloride 10 Docetaxel 10 Cetuximab 10 Capecitabine 10 Albumin-Bound Paclitaxel 10 130-nm albumin-bound paclitaxel 10 Sorafenib 9 Ipilimumab 9 Cisplatin 9 Taxes 8 Oxaliplatin 8 Drug Therapy 8 olaparib 7 abemaciclib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02067143 2021-09-08

LAL1913

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed

Neoplasm Metastasis, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡